The use of monoclonal antibodies (mAbs) in the clinic has successfully expanded to treatment of cancer, viral infections, inflammations, and other indications. However, some of the classes of mAbs that are used in the clinic show the formation of anti-drug antibodies (ADAs) leading to loss of efficacy. This review describes ADA formation for the various mAbs, and its clinical effect. Lastly, this review considers the use of HLA-haplotypes as biomarkers to predict vulnerability of patients sensitive to formation of ADAs.
CITATION STYLE
Mosch, R., & Guchelaar, H. J. (2022, June 17). Immunogenicity of Monoclonal Antibodies and the Potential Use of HLA Haplotypes to Predict Vulnerable Patients. Frontiers in Immunology. Frontiers Media S.A. https://doi.org/10.3389/fimmu.2022.885672
Mendeley helps you to discover research relevant for your work.